Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 630 across all filing types
Latest filing 2021-12-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司第一届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of Chengdu Lead Drug Development Co., Ltd. It details the meeting date, attendance, and specific decisions regarding adjustments to a 2021 restricted stock incentive plan, including the number of shares and recipients. It also mentions compliance with relevant laws and regulations and includes voting results. The document is not a full report but a formal announcement of board decisions related to management and governance matters, specifically about stock incentive plans. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1595 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2021-12-16 Chinese
成都先导药物开发股份有限公司2021年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2021 first extraordinary shareholders' meeting of Chengdu Lead Drug Development Co., Ltd. It details the meeting date, location, attendance, voting results on several proposals related to the company's 2021 restricted stock incentive plan, and legal witness statements confirming the legality of the meeting and resolutions. There is no financial data or report content, but rather the official announcement of the voting results from the shareholders' meeting. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2021-12-16 Chinese
成都先导药物开发股份有限公司关于向2021年限制性股票激励计划激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted stock under the company's 2021 restricted stock incentive plan. It includes information about the number of shares granted, the grant date, the recipients, approval procedures, legal and financial opinions, and accounting treatment of the stock incentive plan. The content focuses on the company's equity incentive plan and the granting of shares to employees and management, which is a capital/financing activity related to share issuance to insiders as part of an incentive program. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy statement or voting result announcement. The document is too detailed and lengthy to be a simple announcement of a report publication. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to the issuance of restricted shares under an equity incentive plan.
2021-12-16 Chinese
成都先导药物开发股份有限公司关于调整2021年限制性股票激励计划首次授予激励对象名单及授予数量的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Chengdu Lead Drug Development Co., Ltd. regarding adjustments to the initial grant of a 2021 restricted stock incentive plan. It details board and supervisory approvals, legal opinions, and adjustments to the number of shares and recipients. The content focuses on stock incentive plan adjustments, approvals, and disclosures, which are related to share-based compensation and capital changes. It is not a full financial report, earnings release, or management discussion. It is also not a proxy statement or voting result announcement. The document is a formal announcement about changes in share-based incentives, which fits best under Share Issue/Capital Change (SHA) as it involves adjustments to stock grants and share quantities under an incentive plan. The document length is 3351 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is SHA with high confidence.
2021-12-16 Chinese
成都先导药物开发股份有限公司第一届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the first Supervisory Board of Chengdu Lead Drug Development Co., Ltd. It details the approval of adjustments to the 2021 restricted stock incentive plan and the granting of restricted stock to incentive recipients. The content focuses on corporate governance decisions related to stock incentives, with no financial statements or earnings data. It is not a full report but an official announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2021-12-16 Chinese
成都先导药物开发股份有限公司关于公司2021年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report by the company regarding insider trading activities related to its 2021 restricted stock incentive plan. It details the investigation of insider information holders and incentive recipients' stock transactions during a specified period, confirming no insider trading occurred. The document references regulatory compliance and internal controls but does not contain financial statements or performance data. It is a regulatory announcement about insider trading compliance related to a stock incentive plan, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1382 characters), and it is a standalone announcement, not a report publication announcement or a full report.
2021-12-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.